LONDON, November 23, 2016 /PRNewswire/ -- Leading IVD Companies in the US, Europe and Asia What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain's new report Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia shows you the prospects of leading IVD companies to 2027. Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027. Our report forecasts to 2027 the overarching IVD market and its main segments: • Point-of-care (POC) tests• Clinical chemistry• Immunochemistry• Haematological diagnostics• Microbiological applications• Genetic testing agents• Other products This report provides profiles, discussions and financial analyses - including revenue forecasts to 2027 - for top US IVD companies: • Danaher• Abbott Laboratories• Johnson & Johnson (J&J)• Bio-Rad• Becton Dickinson• Thermo Fisher Scientific Our report shows you developments and revenue forecasts to 2027 for leading diagnostics companies based in Europe: • Roche• Siemens• bioMérieux This report also provides outlooks and revenue forecasts to 2027 for top Japanesecompanies developing and producing IVD tests: • Sysmex• Arkray To see a report overview please email Sara Peerun on firstname.lastname@example.org Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations: • Dako (Agilent Technologies)• Genomic Health• Laboratory Corporation of America (LabCorp)• MDxHealth• Myriad Genetics• QIAGEN Our 185 page report provides 65 tables and 75 figures covering 7 different IVD submarkets, leading companies in the US, Europe and Asia. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.